252 related articles for article (PubMed ID: 9542527)
1. Death of solid tumor cells induced by Fas ligand expressing primary myoblasts.
Hofmann A; Blau HM
Somat Cell Mol Genet; 1997 Jul; 23(4):249-57. PubMed ID: 9542527
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of solid tumor growth by Fas ligand-expressing myoblasts.
Springer ML; Kraft PE; Blau HM
Somat Cell Mol Genet; 1998 Sep; 24(5):281-9. PubMed ID: 10696236
[TBL] [Abstract][Full Text] [Related]
3. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC.
Hoves S; Krause SW; Halbritter D; Zhang HG; Mountz JD; Schölmerich J; Fleck M
J Immunol; 2003 Jun; 170(11):5406-13. PubMed ID: 12759415
[TBL] [Abstract][Full Text] [Related]
4. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
5. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
Ungefroren H; Voss M; Jansen M; Roeder C; Henne-Bruns D; Kremer B; Kalthoff H
Cancer Res; 1998 Apr; 58(8):1741-9. PubMed ID: 9563493
[TBL] [Abstract][Full Text] [Related]
6. Fas ligand-mediated cytotoxicity is directly responsible for apoptosis of normal CD4+ T cells responding to a bacterial superantigen.
Ettinger R; Panka DJ; Wang JK; Stanger BZ; Ju ST; Marshak-Rothstein A
J Immunol; 1995 May; 154(9):4302-8. PubMed ID: 7536768
[TBL] [Abstract][Full Text] [Related]
7. A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants.
Kang SM; Braat D; Schneider DB; O'Rourke RW; Lin Z; Ascher NL; Dichek DA; Baekkeskov S; Stock PG
Transplantation; 2000 May; 69(9):1813-7. PubMed ID: 10830216
[TBL] [Abstract][Full Text] [Related]
8. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice.
Lau HT; Yu M; Fontana A; Stoeckert CJ
Science; 1996 Jul; 273(5271):109-12. PubMed ID: 8658177
[TBL] [Abstract][Full Text] [Related]
9. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
Hahne M; Rimoldi D; Schröter M; Romero P; Schreier M; French LE; Schneider P; Bornand T; Fontana A; Lienard D; Cerottini J; Tschopp J
Science; 1996 Nov; 274(5291):1363-6. PubMed ID: 8910274
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved.
Kim S; Kim KA; Hwang DY; Lee TH; Kayagaki N; Yagita H; Lee MS
J Immunol; 2000 Mar; 164(6):2931-6. PubMed ID: 10706679
[TBL] [Abstract][Full Text] [Related]
11. Fas ligand (gld)- and Fas (lpr)-deficient mice do not show alterations in the extravasation or apoptosis of inflammatory neutrophils.
Fecho K; Cohen PL
J Leukoc Biol; 1998 Sep; 64(3):373-83. PubMed ID: 9738665
[TBL] [Abstract][Full Text] [Related]
12. Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytes.
Ferrarini M; Imro MA; Sciorati C; Heltai S; Protti MP; Pellicciari C; Rovere P; Manfredi AA; Rugarli C
Int J Cancer; 1999 May; 81(4):573-9. PubMed ID: 10225447
[TBL] [Abstract][Full Text] [Related]
13. Growth of FasL-bearing tumor cells in syngeneic murine host induces apoptosis and toxicity in Fas(+) organs.
Zeytun A; Nagarkatti M; Nagarkatti PS
Blood; 2000 Mar; 95(6):2111-7. PubMed ID: 10706882
[TBL] [Abstract][Full Text] [Related]
14. Induction of FAS ligand expression in a human hepatoblastoma cell line by HCV core protein.
Ruggieri A; Murdolo M; Rapicetta M
Virus Res; 2003 Nov; 97(2):103-10. PubMed ID: 14602201
[TBL] [Abstract][Full Text] [Related]
15. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.
von Bernstorff W; Spanjaard RA; Chan AK; Lockhart DC; Sadanaga N; Wood I; Peiper M; Goedegebuure PS; Eberlein TJ
Surgery; 1999 Jan; 125(1):73-84. PubMed ID: 9889801
[TBL] [Abstract][Full Text] [Related]
17. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors.
Hohlbaum AM; Gregory MS; Ju ST; Marshak-Rothstein A
J Immunol; 2001 Dec; 167(11):6217-24. PubMed ID: 11714783
[TBL] [Abstract][Full Text] [Related]
18. Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway.
Favre-Felix N; Fromentin A; Hammann A; Solary E; Martin F; Bonnotte B
J Immunol; 2000 May; 164(10):5023-7. PubMed ID: 10799856
[TBL] [Abstract][Full Text] [Related]
19. Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells.
Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Okada S; Tokuhisa T; Sakiyama S; Tagawa M
J Immunol; 2002 Sep; 169(5):2241-5. PubMed ID: 12193688
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis provoked by the oxidative stress inducer menadione (Vitamin K(3)) is mediated by the Fas/Fas ligand system.
Caricchio R; Kovalenko D; Kaufmann WK; Cohen PL
Clin Immunol; 1999 Oct; 93(1):65-74. PubMed ID: 10497012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
